title: Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation.
authors.affiliation: Pittsburgh Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
authors.forename: S
authors.initials: S
authors.lastname: Takaya
authors.forename: H
authors.initials: H
authors.lastname: Doyle
authors.forename: S
authors.initials: S
authors.lastname: Todo
authors.forename: W
authors.initials: W
authors.lastname: Irish
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000527:Alprostadil / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001803:Blood Transfusion; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016031:Liver Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009926:Organ Preservation; D011517:Prothrombin Time; D015996:Survival Rate; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000527:Alprostadil